Study in Plerixafor and Granulocyte-colony Stimulating Factor Patients With Relapse Acute Myeloid Leukemia
Status:
Terminated
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
This is a phase 1, dose escalation study of Plerixafor in combination with granulocyte-colony
stimulating factor , Daunorubicin and Cytarabine in adults patients with relapsed acute
myeloid leukemia .
Phase:
Phase 1
Details
Lead Sponsor:
French Innovative Leukemia Organisation
Collaborators:
Acute Leukemia French Association Genzyme, a Sanofi Company